Boomfish Wealth Group LLC Sells 41 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Boomfish Wealth Group LLC decreased its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 5,051 shares of the pharmaceutical company’s stock after selling 41 shares during the period. Vertex Pharmaceuticals accounts for 1.6% of Boomfish Wealth Group LLC’s portfolio, making the stock its 21st largest position. Boomfish Wealth Group LLC’s holdings in Vertex Pharmaceuticals were worth $2,449,000 at the end of the most recent reporting period.

Several other hedge funds have also added to or reduced their stakes in the company. Strategic Advisors LLC boosted its holdings in Vertex Pharmaceuticals by 2.1% during the first quarter. Strategic Advisors LLC now owns 4,580 shares of the pharmaceutical company’s stock worth $2,220,000 after buying an additional 94 shares during the last quarter. Chicago Capital LLC boosted its holdings in Vertex Pharmaceuticals by 1.5% during the first quarter. Chicago Capital LLC now owns 12,406 shares of the pharmaceutical company’s stock worth $6,015,000 after buying an additional 188 shares during the last quarter. Inscription Capital LLC bought a new position in Vertex Pharmaceuticals during the first quarter worth about $272,000. Grimes & Company Inc. boosted its holdings in Vertex Pharmaceuticals by 8.8% during the first quarter. Grimes & Company Inc. now owns 706 shares of the pharmaceutical company’s stock worth $342,000 after buying an additional 57 shares during the last quarter. Finally, Signature Wealth Management Group boosted its holdings in Vertex Pharmaceuticals by 3.5% during the first quarter. Signature Wealth Management Group now owns 4,218 shares of the pharmaceutical company’s stock worth $2,045,000 after buying an additional 143 shares during the last quarter. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

VRTX opened at $450.91 on Tuesday. The business has a fifty day simple moving average of $462.11 and a 200 day simple moving average of $459.98. The company has a market capitalization of $115.79 billion, a PE ratio of -204.96, a price-to-earnings-growth ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1 year low of $377.85 and a 1 year high of $519.88. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35.

Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings data on Monday, May 5th. The pharmaceutical company reported $4.06 earnings per share for the quarter, missing the consensus estimate of $4.29 by ($0.23). The company had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.85 billion. Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. Vertex Pharmaceuticals’s revenue was up 2.6% on a year-over-year basis. During the same period in the prior year, the firm earned $4.76 earnings per share. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts have issued reports on VRTX shares. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, May 6th. Leerink Partnrs lowered Vertex Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, May 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Tuesday, May 6th. Wolfe Research lowered Vertex Pharmaceuticals from an “outperform” rating to a “peer perform” rating in a research report on Wednesday, May 7th. Finally, Royal Bank of Canada raised their price target on Vertex Pharmaceuticals from $420.00 to $423.00 and gave the stock a “sector perform” rating in a research report on Tuesday, May 6th. Fourteen analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Vertex Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus price target of $515.04.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.